Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
Inclusion Criteria: * Patient with multiple myeloma who has received prior treatment with an IMID, PI, and a CD38 monoclonal antibody * Received treatment with an FDA approved BCMA CART cell therapy ide-cel within 1-3 months prior to enrollment * Serum monoclonal protein \< 0.5 gm/dL; 24-hour urine monoclonal protein \< 200 mg; and serum involved free light chains \< 10 mg/dL * No evidence of disease progression based on IMWG criteria * ≥18 years of age at the time of signing informed consent. * ECOG performance status of 0 or 1 * Recovered to Grade 1 or baseline of any non-hematologic toxici…
Talquetamab will be administered SC until disease progression